Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine for severe depression in adults with severe and enduring anorexia nervosa
ISRCTN26462355Phase 2Recruiting
- Sponsor
- King's College London
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and anorexia nervosa (AN), sponsored by King's College London. Primary endpoints: Recruitment feasibility, Lost to follow-up rate and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)anorexia nervosa (AN)
Beyond the preview
Go deeper on ISRCTN26462355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26462355.